MacroGenics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$12.7M
Doctors Paid
415
Transactions
5,252
2024 Total
$1,066
Payment Breakdown by Category
Research$12.7M (99.6%)
Food & Beverage$12,296 (0.1%)
Consulting$7,300 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12.7M | 4,763 | 99.6% |
| Honoraria | $26,778 | 20 | 0.2% |
| Food and Beverage | $12,296 | 460 | 0.1% |
| Consulting Fee | $7,300 | 9 | 0.1% |
Payments by Type
Research
$12.7M
4,763 transactions
General
$46,374
489 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED STUDY OF MARGETUXIMAB PLUS CHEMOTHERAPY VS TRASTUZUMAB PLUS CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH HER2 METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR ANTI-HER2 THERAPIES AND REQUIRE SYSTEMIC TREATMENT | $1.9M | 0 | 376 |
| A PHASE 1 2, FIRST IN HUMAN, DOSE ESCALATION STUDY OF MGD006, A CD123 X CD3 DART BI-SPECIFIC ANTIBODY BASED MOLECULE, IN PATIENTS WITH RELAPSED OR REFRACTORY AML OR INTERMEDIATE-2 HIGH RISK MYELODYSPLASTIC SYNDROME MDS | $1.5M | 0 | 2,765 |
| COMBINATION MARGETUXIMAB, INCMGA00012, MGD013, AND CHEMOTHERAPY PHASE 2 3 TRIAL IN HER2 GASTRIC GEJ CANCER MAHOGANY | $1.3M | 0 | 205 |
| A STUDY OF MGD013 IN PATIENTS WITH UNRESECTABLE OR METASTATIC NEOPLASMS | $1.2M | 4 | 398 |
| MGC018 WITH OR WITHOUT MGA012 IN ADVANCED SOLID TUMORS | $1.1M | 5 | 269 |
| MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER | $936,282 | 4 | 201 |
| NEOADJUVANT PACLITAXEL MARGETUXIMAB PERTUZUMAB COMPARED TO PACLITAXEL TRASTUZUMAB PERTUZUMAB FOR PATIENTS WITH ANATOMIC STAGE II-IIII HER2-POSITIVE BREAST CANCER A RANDOMIZED PHASE II TRIAL | $886,640 | 0 | 3 |
| FLOTETUZUMAB IN PRIMARY INDUCTION FAILURE PIF OR EARLY RELAPSE ER ACUTE MYELOID LEUKEMIA AML | $844,322 | 3 | 136 |
| SAFETY STUDY OF ENOBLITUZUMAB MGA271 IN COMBINATION WITH PEMBROLIZUMAB OR MGA012 IN REFRACTORY CANCER | $654,298 | 3 | 65 |
| A PHASE 1B 2, OPEN LABEL, DOSE ESCALATION STUDY OF MARGETUXIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED REFRACTORY ADVANCED HER2 GASTROESOPHAGEAL JUNCTION OR GASTRIC CANCER | $451,211 | 2 | 68 |
| A PHASE 2 OPEN-LABEL TRIAL TO EVALUATE ENOBLITUZUMAB IN COMBINATION WITH RETIFANLIMAB OR TEBOTELIMAB IN THE FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK | $348,710 | 1 | 94 |
| A PHASE 1 1B DOSE ESCALATION AND COHORT EXPANSION STUDY OF MGC018 IN COMBINATION WITH CHECKPOINT INHIBITOR IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | $292,353 | 0 | 40 |
| A PHASE 1, OPEN LABEL, DOSE ESCALATION STUDY OF MGA271 FC-OPTIMIZED HUMANIZED ANTI-B7-H3 MONOCLONAL ANTIBODY IN PATIENTS WITH REFRACTORY B7-H3-EXPRESSING NEOPLASMS OR NEOPLASMS WHOSE VASCULATURE EXPRESSES B7-H3 | $246,547 | 0 | 27 |
| MGD009 MGA012 COMBINATION IN RELAPSED REFRACTORY CANCER | $230,208 | 1 | 41 |
| A PHASE 1 TRIAL TO EVALUATE THE SAFETY OF SINGLE AGENT FLOTETUZUMAB IN ADVANCED CD123-POSITIVE HEMATOLOGICAL MALIGNANCIES | $147,204 | 0 | 6 |
| TRIAGE OF ADVANCED CERVICAL CANCER THROUGH IMMUNOTHERAPY INDUCTION TRACTION | $145,823 | 0 | 3 |
| A PHASE 1, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MGD007, A HUMANIZED GPA33 X CD3 DART PROTEIN IN PATIENTS WITH RELAPSED REFRACTORY METASTATIC COLORECTAL CARCINOMA | $81,197 | 0 | 1 |
| SAFETY STUDY OF MGD009 IN B7-H3-EXPRESSING TUMORS | $78,088 | 0 | 4 |
| A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | $73,675 | 0 | 16 |
| A PHASE II TRIAL OF NEOADJUVANT ENOBLITUZUMAB MGA271 IN MEN WITH LOCALIZED INTERMEDIATE- AND HIGH-RISK PROSTATE CANCER | $64,732 | 0 | 3 |
| A PHASE 1, DOSE ESCALATION STUDY OF MGAH22 IN PATIENTS WITH REFRACTORY HER2 POSITIVE BREAST CANCER AND PATIENTS WITH OTHER HER2 POSITIVE CARCINOMAS FOR WHOM NO STANDARD THERAPY IS AVAILABLE | $59,746 | 0 | 4 |
| A PHASE 1B 2, OPEN LABEL, DOSE ESCALATION STUDY OF MGD007, A HUMANIZED GPA33 CD3 DART PROTEIN IN COMBINATION WITH MGA012, AN ANTI-PD-1 ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY METASTATIC COLORECTAL CARCINOMA | $59,581 | 1 | 13 |
| A PHASE 3, RANDOMIZED STUDY OF MARGETUXIMAB PLUS CHEMOTHERAPY VS TRASTUZUMAB PLUS CHEMOTHERAPY IN THE TREATMENT OF PATIENTS WITH HER2 METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR ANTI HER2 THERAPIES AND REQUIRE SYSTEMIC TREATMENT | $28,990 | 0 | 8 |
| A PHASE 1 STUDY OF MGD020 AS A SINGLE AGENT OR IN COMBINATION WITH MGD014 IN PERSONS WITH HIV-1 ON ANTIRETROVIRAL THERAPY | $23,649 | 0 | 3 |
| Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer | $11,530 | 0 | 4 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Dr. Nora Bucher, Md, MD | Internal Medicine | Vancouver, WA | $592.00 | $0 |
| Yeo Jin Moon, Arnp, ARNP | Family | Seattle, WA | $221.55 | $0 |
| Dr. Ben Chue, M.d, M.D | Hematology & Oncology | Seattle, WA | $221.55 | $0 |
| Dr. Sumit Subudhi, Md, Phd, MD, PHD | Medical Oncology | Houston, TX | $155.65 | $0 |
| Dr. Ana Aparicio | Hematology & Oncology | Houston, TX | $155.65 | $0 |
| Unknown Provider | — | — | $143.40 | $0 |
| Xiao Wei, Md, MD | Medical Oncology | Boston, MA | $141.34 | $0 |
| Dr. Marcia Cruz-Correa, Md, MD | Gastroenterology | Rio Piedras, PR | $141.34 | $0 |
| Gabrielle D'amore, Pa-C, PA-C | Physician Assistant | Royal Oak, MI | $125.00 | $0 |
| Meera Iyengar, Md, MD | Medical Oncology | Clermont, FL | $125.00 | $0 |
| Dr. Ernesto Bustinza Linares, M.d, M.D | Medical Oncology | Deland, FL | $125.00 | $0 |
| Melinda Moore Gottschalk | Physician Assistant | Round Rock, TX | $125.00 | $0 |
| Dr. Jason Luke, M.d, M.D | Hematology & Oncology | Pittsburgh, PA | $117.00 | $0 |
| Dr. Nicola Jabbour, M.d, M.D | Hematology & Oncology | Lexington, KY | $98.33 | $0 |
| Dr. Chandler Park, M.d., Msc, M.D., MSC | Hematology & Oncology | Corydon, IN | $97.50 | $0 |
| Dr. Jeffrey Hargis, M.d, M.D | Hematology & Oncology | Louisville, KY | $97.50 | $0 |
| Christos Vaklavas, M.d, M.D | Hematology & Oncology | Birmingham, AL | $96.00 | $0 |
| Dr. Mark Burkard, M.d, M.D | Internal Medicine | Iowa City, IA | $96.00 | $0 |
| Shou-Ching Tang, M.d, M.D | Medical Oncology | Augusta, GA | $96.00 | $0 |
| Hardik Chhatrala, Md, MD | Hematology & Oncology | Jacksonville, FL | $93.12 | $0 |
| Ashley Harris, Arnp, ARNP | Adult Health | Jacksonville, FL | $93.12 | $0 |
| Laura Lourdes, M.d, M.D | Hematology & Oncology | Jacksonville, FL | $93.11 | $0 |
| Dr. Miten Patel, M.d, M.D | Hematology & Oncology | Jacksonville, FLORIDA | $93.11 | $0 |
| Dr. Maria Valente, M.d, M.D | Hematology & Oncology | Jacksonville, FL | $93.11 | $0 |
| Dr. Bernard Tawfik, Md, MD | Internal Medicine | Albuquerque, NM | $91.01 | $0 |
About MacroGenics, Inc.
MacroGenics, Inc. has made $12.7M in payments to 415 healthcare providers, recorded across 5,252 transactions in the CMS Open Payments database. In 2024, the company paid $1,066. The top product by payment volume is MARGENZA ($4.7M).
Payments were distributed across 31 medical specialties. The top specialty by payment amount is Hematology & Oncology ($193,476 to 140 doctors).
Payment categories include: Food & Beverage ($12,296), Consulting ($7,300), Research ($12.7M).
MacroGenics, Inc. is associated with 1 products in the CMS Open Payments database.